ClinicalTrials.gg
Not yet recruitingNCT03585738IPOSI-1Updated Nov 5, 2020

Effects of Oral Inositol Supplementation on Obstetrics Outcomes in PCOS Women

An interventional study of Inositol + Folic acid and Folic acid in Polycystic Ovary Syndrome, sponsored by Università degli Studi dell'Insubria. Not yet recruiting. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-05.

Sponsored by Università degli Studi dell'Insubria · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies testing inositol in Polycystic Ovary Syndrome — 5 open to participants now, 6 under way, 1 of them phase 3. Inositol · Polycystic Ovary Syndrome.

Planned enrollment
14th of 32
80 · median 73
Started
2022
with 3 others
No phase
19 of 33
2 open now
Registered
13th of 33
by date
Lead sponsor
2 of 33
Università degli Studi dell'Insubria

Among the 33 studies testing inositol in Polycystic Ovary Syndrome, this one is the 14th largest by planned enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2022, is one of 19 with no phase, and was the 13th registered.

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

5 of the 33 studies testing inositol in Polycystic Ovary Syndrome are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About inositol

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 40 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing inositol in Polycystic Ovary Syndrome, or all of them as a file.
02

Study summary

Polycystic ovarian syndrome (PCOS) is a heterogeneous, multifaceted and complex disorder characterized by insulin resistance (IR), hyperinsulinemia, and hyperandrogenism leading ovarian disfunction and infertility. Given the central pathogenic role of IR in the endocrine, reproductive, and metabolic disturbances of PCOS, several pharmacological and non-pharmacological approaches have been proposed to counteract the hyper insulinemic IR typical of the syndrome. Two Inositol stereoisomers, Myo-Inositol (MI) and D-chiro-inositol (DCI), captured the attention of researchers for their insulin-sensitizing actions, which configure them as proper candidates for the treatment of PCOS.

Very few studies reported on spontaneous clinical pregnancy rates, none were powered for this outcome, and none reported on the clinically relevant outcome of live birth. Therefore, data about clinical pregnancy rate, live birth rate, and miscarriage rate comparing inositols with placebo are limited.

Nevertheless, regarding infertility the primary outcomes that should be considered are clinical pregnancy rate, miscarriage rate and live birth rate. Although many studies showed improved hormonal and metabolic profile and improved ovulation rate and higher quality and number of oocyte retrieved in Assisted Reproductive Technology (ART) in PCOS women after inositols administration, data about clinical pregnancy rate, live birth rate, and miscarriage rate are limited with several concerns regarding interpretation of the studies.

Furthermore, independently by the effect on PCOS related infertility, few data are available about the role of inositol on obstetrics outcomes of pregnancies conceived after treatment with inositol and/or orally supplemented during pregnancy. Considering that the combination of MI and DCI alleviate many of the metabolic dysregulations typical of PCOS thanks to insulin-sensitizing actions, it is plausible consider a beneficial effects on pregnancy complications such as gestational diabetes and preeclampsia.

03

Conditions studied

  • Polycystic Ovary Syndrome

Keywords

  • Inositol
  • Polycystic ovarian syndrome
  • Pregnancy
  • Obstetrics outcomes
  • Gestational diabetes
  • Preeclampsia
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnancy spontaneously conceived in women with PCOS diagnosed by Rotterdam criteria that starts oral supplementation before conception.

Exclusion criteria

Exclusion Criteria:

  • Any kwon pre-pregnancy disease.
  • Any other pharmacological, non-pharmacological or nutraceutical treatment (beside oral folic acid supplementation) more than 3 months before the enrollment () or during the trial, or until the development or pregnancy-induced/related diseases requiring pharmacological treatments.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Inositol + Folic acid

    Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Inositol (Myo-inositol and D-chiro-inositol at 40:1 ratio) plus Folic acid before spontaneous conception until delivery.

    Dietary Supplement: Inositol + Folic acid

  • Placebo comparator
    Folic acid

    Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Folic acid before spontaneous conception until delivery.

    Dietary Supplement: Folic acid

Interventions

  • Dietary supplementInositol + Folic acid

    Drug pages: InositolStudies of InositolInositol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Folic AcidStudies of Folic AcidFolic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Daily oral supplementation before spontaneous conception until delivery: Myo-Inositol: 1100 mg D-chiro-inositol: 27.6 mg Folic acid: 400 mcg

  • Dietary supplementFolic acid

    Daily oral supplementation before spontaneous conception until delivery: Folic acid: 400 mcg

06

What researchers measure

Primary outcomes

  1. Gestational diabetes prevalence

    Gestational diabetes prevalence: number of women that develop gestational diabetes diagnosed based on oral glucose tolerance test (OGTT) cut-off (92 - 180 - 153 mg/dl).

    Time frame: During pregnancy at 16-18 week or 24-28 weeks as recommended

  2. Preeclampsia prevalence

    Preeclampsia prevalence: number of women that develop preeclampsia diagnosed based on blood pressure higher than 140/90 mmHg after 20 week of gestation plus 24h proteinuria higher that 300mg.

    Time frame: During pregnancy after the 20 week of gestation

  3. Birth weight

    gr

    Time frame: At delivery.

  4. Weight gain in pregnancy

    Kg

    Time frame: Change in weight before pregnancy and at the 38 week of gestation

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2022; primary completion for Dec 2024, 35 months later.

Of 205 non-industry interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 35 months is above that.

Counting every sponsor, half of 220 studies reached it within 17 months; a quarter within 7 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2018
First posted
Jul 13, 2018
StartEst.
Jan 1, 2022
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2026
Last update
Nov 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03585738
Lead sponsor
Università degli Studi dell'Insubria
Responsible party
Antonio Simone Laganà (Principal Investigator, Università degli Studi dell'Insubria) — Principal investigator
First posted
Jul 13, 2018
Start date
Jan 1, 2022 (estimated)
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 5, 2020

Study contacts

Antonio Simone Laganà, M.D.
Contact
antoniosimone.lagana@asst-settelaghi.it
+39 329 6279579
Simone Garzon, M.D.
Contact
simone.garzon@univr.it
+39 347 0782287
Antonio Simone Laganà, M.D.
principal investigator · Università degli Studi dell'Insubria
Simone Garzon, M.D.
principal investigator · Univerisity of Verona
Fabio Ghezzi, M.D.
study chair · Università degli Studi dell'Insubria
Massimo Franchi, M.D.
study chair · Univerisity of Verona
Antonella Cromi, M.D.
principal investigator · Università degli Studi dell'Insubria

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Inositol · Folic Acid

Start the discussion